- Pharma company Viiv’s attempt to secure patents for key HIV drugs dolutegravir and cabotegravir opposed in India
- India, EFTA look to restart stalled trade talks
- PhRMA Special 301 submission 2016
- US pharma body slams Indian patent regime
- US wants bilateral treaty modelled on India’s FTAs with Japan & South Korea
IBSA News, Sep 19 2011
India’s generic drugs are a lifeline not only for millions of poor people in India, but also to developing countries in Africa, Asia and Latin America. So much so that India is known as the ‘pharmacy to the developing world’.
But India, which built up its pharmaceutical industry by ignoring patents for decades, was forced to adhere to World Trade Organisation (WTO) intellectual property regulations in 2005. It is also now busily signing various bilateral trade deals with Western countries, seriously threatening the world’s supply of cheap, essential drugs.
Leena Menghaney a lawyer with Médecins Sans Frontières (Doctors Without Borders) in India says the worst affected are likely to be people on anti-retroviral drugs, since about 80 percent of the world’s anti-AIDS drugs and 92 percent of drugs for children with AIDS comes from India.
View the Slideshow here